Presence of ductal carcinoma in situ confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma

Author(s)

A.F. Logullo ^[1] ; A.B. Godoy ^[2] ; M. Mourão-Neto ^[3] ; A.J.G. Simpson ^[4] ; I.N. Nishimoto ^[5] ; M.M. Brentani ^[6]

Affiliation

^[1] Universidade de São Paulo. Faculdade de Medicina. Departamento de Radiologia - Brasil

^[2] Instituto Ludwig de Pesquisa sobre o Câncer - Brasil

^[3] Hospital do Câncer A.C. Camargo - Brasil

^[4] Instituto Ludwig de Pesquisa sobre o Câncer - Brasil

^[5] Hospital do Câncer A.C. Camargo - Brasil

^[6] Universidade de São Paulo. Faculdade de Medicina. Departamento de Radiologia - Brasil

• Document type: Journal article
• Source: Brazilian Journal of Medical and Biological Research; v. 35, n. 8, p. 913-919, 2002-08-00.

Abstract

We have retrospectively analyzed a series of 155 sequential cases of T1N0M0 ductal carcinomas of which 51 tumors had a ductal carcinoma in situ (DCIS) component for correlation between the presence of DCIS and clinicopathological variables, recurrence and patient survival. No correlations between the presence of DCIS and age, menopausal status, size, estrogen or progesterone receptors were found. High-grade infiltrative tumors tended not to present a DCIS component (P = 0.08). Patients with tumors associated with DCIS form a subgroup with few recurrences (P = 0.003) and good survival (P = 0.008). When tumors were classified by size, an association between large tumors (>1.0 cm) and increased recurrence and shortened overall survival was found. The presence of DCIS in this subgroup significantly reduced the relative risk of death. (AU)

• FAPESP's process: 99/12641-1 - Molecular aspects of hematopoetic cell-bone morrow stroma interactions
• Grantee: Maria Mitzi Brentani
• Support Opportunities: Research Projects - Thematic Grants